Business Goal - Transition all systems to use the new AML process over the next year.
业务战略目标——明年把所有系统转换为使用新的AML过程。
Business Objective - in the first month of using the new AML process is expected that 10,000 AML checks will have been done.
业务战术目标——在使用新的AML过程的第一个月，预计会完成10,000次AML检查。
Working from the example above, an architect might assess that a business directive (i.e. for AML) should be applied to "tellers".
对于上面的示例，架构师可能断定一个业务指示（例如AML）应该应用于 “出纳员”。
Acute myelogenous leukemia (AML) is a cancer of the blood and bone marrow - the spongy tissue inside bones where blood cells are made.
急性骨髓性白血病(aml)是指血液中和骨髓中的细胞发生了癌变——骨髓是指骨内作为造血场所的海绵组织。
Systems processing AML processes have the need to feedback any insight gained on money transaction inconsistencies back to the MDM system.
处理AML过程的系统需要把发现的金融交易异常返回给MDM系统。
MDR was a targeted antigen in drug resistance AML.
MDR也是耐药白血病治疗的较好靶抗原。
Patients with AML need to start chemotherapy right away.
急粒患者需要立刻接受化疗。
To give strong doses of chemotherapy to kill more AML cells.
可以用大剂量的化疗来杀死更多的AML细胞。
Induction therapy for children with AML starts with 2 or 3 drugs.
对于这些急粒患儿，诱导治疗一开始就需使用2 ~3种药物。
With AML, the leukemic cells are often referred to as blast cells.
对于急性髓细胞白血病，白血病细胞通常是指原始细胞。
DR5 may play an important role in TRAIL-inducing apoptosis of AML cells.
DR5在TRAIL介导的急性髓系白血病细胞凋亡中起重要的作用。
Objective: To study the biological and clinical significance of CD7 + CD56 + AML.
目的：探讨CD 7 + CD56 +急性髓系白血病(aml)的临床生物学意义。
The alteration of the telomere length was detected mainly in telomerase-positive AML.
端粒长度的变化主要发生在端粒酶活性高表达的白血病细胞中。
When the donor cells attack the AML cells it is called "graft versus leukemia" or GVL.
供者的细胞攻击患者的AML细胞，这被称为“移植物抗白血病效应”(GVL)。
Amelogenin (AML) gene locates on the conservative region of the bovine X and Y chromosomes.
牛牙釉蛋白(AML)基因定位于牛x染色体和Y染色体上的同源区域。
Objective to study the factors that affect the recent curative effect on AML with t (8; 21).
目的研究影响伴t(8； 21)急性髓系白血病(aml)近期疗效的因素。
Objective: To explore the characteristic of immunophenotyping in acute myeloid leukemia (AML).
目的：探讨急性髓细胞白血病(aml)的免疫表型特点。
Some patients still have AML cells in their marrow even after treatment. This is called refractory leukemia.
有些患者甚至在治疗后其骨髓中仍然存有aml细胞。这叫做难治性白血病。
Objective To explore the expression of P170 protein in untreated elder AML and its correlation with prognosis.
目的检测P170糖蛋白在初治老年急性髓系白血病（AML）的表达，并探讨其与预后的关系。
These intriguing results need to be validated in a randomized clinical trial of a large cohort of AML patients.
这些有趣的结果尚需大规模AML患者参与的随机对照试验来验证。
Objective To report a case of acute myeloid leukemia (AML) with CD7 + near-tetraploid clones by doublet(8; 21).
目的报道1例以CD7+和双重t（8；21）易位为特征的近四倍体克隆急性髓细胞性白血病（AML）。
Thus the research on the strategic design of AML becomes integrated and beyond the area of economy and finance.
因此，开展反洗钱的战略设计方面的研究，也就成为超越经济和金融领域的、带有全局性的研究。
OBJECTIVE: to evaluate effect of autologous hematopoietic stem cell transplantation on the treatment of acute AML.
目的：评价自体造血干细胞移植对急性髓系白血病的改善效果。
The management of microbial infection is one of the important issues for patients with acute myeloid leukemia (AML).
微生物感染的治疗是急性髓样白血病（AML）患者面临的重要问题之一。
Objective To explore the immunophenotype of children with acute myeloid leukemia (AML) and its clinical significance.
目的探讨儿童急性粒细胞白血病(aml)免疫分型及其临床意义。
Conclusion The immunophenotype analysis of AML combined with FAB classification may help in AML diagnosis and typing.
结论结合FAB分类，多参数流式细胞术有助于对AML的准确诊断和分型。
Background and objective: Relapse AML, refractory AML, AML in the old and secondary AML are all AML subtypes hard to cure.
背景和目的：难治性急性髓系白血病(aml)包括复发性aml、原发耐药aml、老年aml及继发aml，是目前白血病治疗困难的类型。
AML is a hard blood cancer to cure. The good news is that there has been improvement in treatment results in recent years.
急性髓细胞性白血病(aml)很难治愈，不过可喜的是近年来疗效已有所改善。
Using genomic PCR and sequencing, FLT3/ITD mutation with or without chromosome translocation were examined in AML patients.
采用PCR联合序列检测伴有或不伴有染色体易位的急性髓性白血病患者FLT3基因突变情况。
It is concluded that TRAIL can kill AML cells through inducing apoptosis, and TRAIL has a promising prospect in clinical use.
结论：TRAIL能通过诱导细胞凋亡而杀伤aml细胞，是一种有望应用于临床白血病治疗的新型生物制剂。
应用推荐